You are here

Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

Last updated on March 14, 2019

Study Location
University of Alabama Hospital
Birmingham, Alabama, 35294 United States
Eligibility criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Sickle Cell Disease, Vaso-occlusive Crisis, Pain Crisis
Females and Males
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
12-60 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. 12 to 60 years of age

2. Confirmed diagnosis of sickle cell disease (HbSS or HbS-β0thalassemia)

3. Diagnosis of VOC at the time of enrollment

4. Hospitalized or in process of admission at the time of enrollment

5. Able to receive the first dose of study drug within 24 hours of initial medical
evaluation in the Emergency Department/clinic for VOC;

o Subjects treated as an outpatient within the past 48 hours for the same VOC episode
may be enrolled if dosing is also expected within 24 hours of their second (admitting)

6. Documented and observed written informed consent (and assent, where applicable)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Infection, diagnosed or strongly suspected, as evidenced by one or more of the

- Fever >39°C (102.2°F)

- In the presence of fever ?38.5°C (101.3°F), 1 of the following:

- Positive findings (suspicious for infection) on diagnostic tests, such as
cerebral spinal fluid [CSF] evaluation, radiographs, or bacterial culture of
normally sterile sites

- Exam findings leading to diagnosed or strongly suspected bone or joint

- Determination by physician that bacterial or serious systemic viral
infection is likely (eg, influenza, mononucleosis)

- Subjects may be included with uncomplicated urinary tract infections
(provided they do not have fever ?38.5° C [101.3° F] or costo-vertebral
angle [CVA] tenderness), and/or suspected minor viral syndromes (upper
respiratory infection symptoms but no symptoms suggestive of bacterial
infection other than uncomplicated otitis media or uncomplicated
streptococcal pharyngitis)

2. Acute chest syndrome, diagnosed or strongly suspected, as evidenced by a new
infiltrate on chest radiograph, and 1 or more of the following:

- Fever >39° C (102.2° F)

- Hypoxia (confirmed by arterial blood gases [ABG] with paO2

- Chest pain

- Suspicious findings on exam (tachypnea, intercostal retractions, wheezing, and/or

3. Sickle cell disease (SCD) pain atypical of VOC, including hepatic or splenic
sequestration, cholecystitis, or pneumonia.

4. Acute stroke, acute priapism, severe avascular necrosis of the hip/shoulder when the
presenting pain is only in the affected hip/shoulder

5. Serum creatinine:

- >1.2 mg/dL for subjects 16 to 60 years of age

- >1.0 mg/dL for subjects 12 to 15 years of age

6. Alanine transaminase (ALT/SGPT) >2x upper limit of normal (ULN) (based on clinic
laboratory normal range)

7. Hemoglobin

8. Platelets

9. Recent (within the past 30 days) major surgery, hospitalization for other than VOC,
documented serious bacterial infection requiring antibiotic treatment, or significant

10. Hospitalization for uncomplicated VOC, or treated with parenteral pain medications in
other medical settings such as the emergency department or day hospital for
uncomplicated VOC, within past 14 days.

o Subjects may be included if treated as an outpatient within the past 48 hours for
the same VOC episode.

11. Recent (within the past 90 days) cerebrovascular accident, transient ischemic attack,
or seizure

12. pRBC transfusions in the past 14 days

13. Systemic steroid therapy within 48 hours prior to enrollment or expectation that
therapy may be used during the study (inhaled or topical steroids are allowed)

14. For those on chronic or long-acting opioids, a change in dose in the past 14 days OR
pain requiring medical attention in the past 14 days (change in opioid medication for
acute pain in the past 48 hours and directly related to this VOC admission is allowed)

15. Greater than 5 episodes of hospitalization for VOC in the past 6 months (180 days)

16. Medical or psychiatric condition that, in the opinion of the investigator, may pose a
risk to the subject for participation or interfere with the conduct or results of the

17. Currently receiving, or has received within the previous 4 weeks, any other
investigational agent

18. Previous administration of GMI-1070

19. Expectation that the subject will not be able to be followed for the duration of the

20. Pregnant or lactating female; or female of childbearing potential or male unable or
unwilling to comply with birth control methods or abstinence during the course of the

21. Active use of illicit drugs and/or alcohol dependence, as determined by the

Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis


Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center


[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Sickle Cell Anemia, Sickle Cell Disease, Sickle Cell Disorders, Pain Crisis, Vaso-occlusive Crisis
All Genders
Multiple Sites


Contact a representative by phone, email, or visiting the study website. Please see the references below:


Pfizer Clinical Trials Contact Center




[email protected]

Call Now